Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.

Phase 2

• Conditions: Renal Cell Carcinoma
• Interventions: Drug: Nivolumab; Drug: Ipilimumab

• Registration Number: NCT04134182
• Lead Sponsor: Kidney Cancer Research Bureau

Brief Summary

The aim of this Phase 2 study is to evaluate the efficacy and safety of nivolumab, an anti-PD-1 antibody, and ipilimumab, an anti-CTLA-4 antibody, in T1aN0M0 clear-cell RCC patients ineligible for surgical treatment.

Detailed Description

Surgery remains the standard curative-intent therapy for localized renal cell carcinoma (RCC). Thus, systemic therapy for RCC should still be considered only in patients who have contraindications to surgery.

Results of Phase 3 CheckMate 214 study showed that a combination of nivolumab and ipilimumab has a significant impact on tumor burden in intermediate- and poor-risk metastatic RCC patients with a complete response rate of 11% (Motzer et al. Lancet Oncology 2019). Median time to objective response was 2.8 months. Among all complete responders to nivolumab plus ipilimumab in the intention-to-treat population, 5% achieved a complete response at the first scan, whereas most converted from the partial response at a median of 6.9 months or from the stable disease at a median of 11.3 months.

We hypothesize that this combination could completely eliminate primary tumors in patients with small primary (less than 4 cm) ineligible for surgical treatment. There are no studies evaluating checkpoint inhibitors in this setting in RCC patients.

Study Timeline

• Study Start: 2019-10-16
• Study First Submitted: 2019-10-18
• Study First Submitted QC: 2019-10-18
• Study First Posted: 2019-10-22
• Status Verified: 2020-12
• Last Update Submitted: 2020-12-22
• Last Update Posted: 2020-12-23
• Primary Completion: 2021-09
• Study Completion: 2021-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

1. Cytologically proven clear-cell RCC
2. CT-confirmed measurable primary tumor less than 4 cm and no evidence of extranodal metastatic disease (T1aN0M0)
3. Inability to perform surgery for any reason (functional single kidney with a central, high-complexity RCC, high risk of nephrectomy and dialysis, patients with complex coagulation disorders, etc.) or preference of patient is to have no surgery for any reason
4. No contradictions to nivolumab and ipilimumab
5. Age 18 or older
6. Written informed consent

Exclusion Criteria

1. prior treatment for RCC
2. pregnant or nursing
3. history of serious hypertension, cardiac arrhythmia, congestive heart failure, angina pectoris, or another severe cardiovascular disease (i.e., New York Heart Association class III or IV)
4. evidence of metastatic disease
5. local and/or systemic infections requiring antibiotics within 28 days prior to study entry
6. other malignancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Nivolumab + Ipilimumab	Ipilimumab	Patients will receive a combination of ipilimumab, followed by nivolumab for 16 weeks.
Nivolumab + Ipilimumab	Nivolumab	Patients will receive a combination of ipilimumab, followed by nivolumab for 16 weeks.

Primary Outcome Measures

Name	Time	Method
Complete Response Rate	16 weeks	percentage of patients with localized RCC who have no tumor in kidney

Secondary Outcome Measures

Name	Time	Method
Objective response rate	16 weeks	percentage of patients with localized RCC who have no tumor in kidney or tumor shrinkage more than 30%
3-year disease-free survival rate	3 years	percentage of patients who are disease free at 3 years after treatment start
5-year survival rate	5 years	percentage of patients who are alive at 5 years after treatment start
Rate of adverse events	16 weeks	percentage of patients who have adverse events

Trial Locations

Locations (2)

Russian Scientific Center of Roentgenoradiology; 🇷🇺 Moscow, Russian Federation

N.N. Blokhin Russian Cancer Research Center; 🇷🇺 Moscow, Russian Federation